These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 15586352)

  • 1. The clinical use of angiotensin-converting enzyme inhibitors.
    Wong J; Patel RA; Kowey PR
    Prog Cardiovasc Dis; 2004; 47(2):116-30. PubMed ID: 15586352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M; Solomon SD
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
    Brugts JJ; van Vark L; Akkerhuis M; Bertrand M; Fox K; Mourad JJ; Boersma E
    Int J Cardiol; 2015 Feb; 181():425-9. PubMed ID: 25569271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    Pfeffer MA
    Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
    Mercier K; Smith H; Biederman J
    Prim Care; 2014 Dec; 41(4):765-78. PubMed ID: 25439533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence.
    Dézsi CA
    Am J Cardiovasc Drugs; 2014 Jun; 14(3):167-73. PubMed ID: 24385234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blockers: evidence for preserving target organs.
    Carson P; Giles T; Higginbotham M; Hollenberg N; Kannel W; Siragy HM
    Clin Cardiol; 2001 Mar; 24(3):183-90. PubMed ID: 11288962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mega clinical trials which have shaped the RAS intervention clinical practice.
    Düsing R
    Ther Adv Cardiovasc Dis; 2016 Jun; 10(3):133-50. PubMed ID: 27271312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects.
    Silverstein RL; Fenves AZ; Ram CV
    Postgrad Med; 2004 Aug; 116(2):31-8, 41. PubMed ID: 15323152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should ACE inhibitors and ARBs be used in combination in children?
    Stotter BR; Ferguson MA
    Pediatr Nephrol; 2019 Sep; 34(9):1521-1532. PubMed ID: 30112656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias.
    Garg S; Narula J; Marelli C; Cesario D
    Am J Cardiol; 2006 Mar; 97(6):921-5. PubMed ID: 16516603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Angiotensin receptor blockers in cardiovascular disease.
    Maggioni AP
    Cardiovasc Drugs Ther; 2006 Aug; 20(4):295-308. PubMed ID: 16915347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension.
    Weber MA
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):189S-194S. PubMed ID: 10619571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to blockade of the renin-angiotensin-aldosterone system: evidence from randomized controlled trials (RCTs) of angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers--questions remain unsolved.
    Ueda S
    J Pharmacol Sci; 2010; 113(4):292-5. PubMed ID: 20675956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
    Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
    J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of renin angiotensin system in heart failure post-myocardial infarction: what is the best therapy?
    E Gullo C; de Almeida Zia VA; Vilela-Martin JF
    Recent Pat Cardiovasc Drug Discov; 2014; 9(1):28-37. PubMed ID: 24993597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Angiotensin-converting enzyme inhibitors. Current indications].
    Mitu F; Rădoi D
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(1):23-31. PubMed ID: 21495292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.